Healthcare is a sector that remains in high demand regardless of economic conditions. From birth to death, healthcare services are essential, making companies like Johnson & Johnson and Abbott Laboratories attractive investments for many. These two industry giants have a long history of stability and growth, making them popular choices among investors.
Johnson & Johnson, with a market cap of approximately $589 billion, operates in prescription drugs and medical devices, enjoying a global presence in the healthcare industry. Its stock price has seen an 18% increase year-to-date, trading at around $244. On the other hand, Abbott Labs, with a market cap of around $179 billion, focuses on developing medical devices that extend healthcare beyond hospitals into the home. Despite trading at roughly $102 per share, Abbott’s stock is down about 18% since the start of the year.
Comparing the two companies’ latest quarterly results, Johnson & Johnson outperformed Abbott in terms of sales and net income. JNJ generated $24.56 billion in sales and $5.12 billion in net income, significantly higher than Abbott’s $11.46 billion in sales and $1.78 billion in net income. However, when it comes to valuation metrics like price-to-earnings ratio and price-to-sales ratio, Abbott appears to be the cheaper option.
Both companies have a strong track record of increasing dividends, with Johnson & Johnson paying a forward annual dividend of $5.20 per share and Abbott Labs paying $2.52 per share. While Johnson & Johnson has a higher yield of around 2.13%, Abbott offers a slightly higher yield of 2.46%. Both companies have consistently increased their dividends for over 50 years, indicating their commitment to rewarding shareholders.
Analysts’ opinions on the two stocks vary, with a consensus rating of “Moderate Buy” for Johnson & Johnson and a “Strong Buy” for Abbott Laboratories. Wall Street seems to favor Abbott as the more attractive pick based on its cheaper valuation, higher potential upside, and stronger analyst recommendations.
In conclusion, both Johnson & Johnson and Abbott Laboratories are solid investments in the healthcare sector, with a long history of dividend growth and stability. While Johnson & Johnson may have a larger scale and profitability, Abbott appears to offer better value and potential for growth according to Wall Street analysts. Investors looking for a reliable dividend aristocrat may find both companies appealing choices for their portfolios.
